Debiopharm is a well-established, family-owned biopharmaceutical group of companies based in Lausanne, Switzerland.
Founded in 1979 by Rolland-Yves Mauvernay, Debiopharm identifies high-potential compounds for in-licensing, clinical development and commercialization with partners across the globe.
Innovation is central to the company, with 1,200,000 patients benefiting from the development of innovative therapies each year that target high, unmet medical needs in oncology and bacterial infections.
Debiopharm’s quest to improve patient quality of life through excellence in drug development, drug manufacturing, and digital health has led to the release of 2 standard-of-care cancer therapies, a series of successful investments in disruptive healthcare startups like Biocartis or Kaiku, and a growing pipeline of specialized medicines that respond to unmet medical needs.
Debiopharm has a vision for healthcare which goes well beyond making new medicines available. Investing in patients through clinical trials while keeping innovation central in all they do, Debiopharm has earned its title as a true Swiss Biotech Success Story.